3.3841

8.51% -0.3159

Fulcrum Therapeutics Inc (FULC)

Overview News Price History Option Chain Financials Discussions Forecast

Fulcrum Therapeutics Inc stock is traded at $3.3841, with a volume of 124.89K. It is down -8.51% in the last 24 hours and down -18.63% over the past month. Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Previous Close:

$3.70

Open:

$3.67

24h Volume:

124.89K

Relative Volume:

0.18

Market Cap:

$199.57M

Revenue:

$2.81M

Net Income/Loss:

$-97.34M

P/E Ratio:

-2.1418

EPS:

-1.58

Net Cash Flow:

$-91.47M

1W Performance:

-11.85%

1M Performance:

-18.63%

6M Performance:

-65.25%

1Y Performance:

-65.21%

1-Day Range:

$3.33

$3.84

1-Week Range:

$3.33

$3.91

52-Week Range:

$2.86

$13.70

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name

Fulcrum Therapeutics Inc

Sector

Healthcare (1183)

Industry

Biotechnology (674)

Phone

617-651-8851

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

Twitter

@fulcrumtx

Next Earnings Date

2024-11-05

Latest SEC Filings

FULC's Discussions on Twitter

Compare FULC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FULC Fulcrum Therapeutics Inc	3.385	199.57M	2.81M	-97.34M	-91.47M	-1.58
VRTX Vertex Pharmaceuticals Inc	483.00	123.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	709.82	79.09B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	627.10	37.97B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	249.60	31.74B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	259.84	27.71B	3.32B	-860.46M	-1.04B	-8.32

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-12-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-12-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-12-24	Downgrade	Stifel	Buy → Hold
Sep-09-24	Upgrade	BofA Securities	Underperform → Neutral
May-20-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-24	Initiated	RBC Capital Mkts	Outperform
Sep-25-23	Initiated	Goldman	Neutral
Aug-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Aug-22-23	Upgrade	Stifel	Hold → Buy
May-04-23	Downgrade	Goldman	Buy → Neutral
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-09-23	Downgrade	Stifel	Buy → Hold
Feb-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-24-23	Downgrade	BofA Securities	Neutral → Underperform
Nov-15-22	Initiated	Goldman	Buy
Mar-08-22	Initiated	Oppenheimer	Outperform
Mar-03-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-11-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-22-21	Initiated	Credit Suisse	Outperform
Mar-02-21	Initiated	Stifel	Buy
Oct-16-20	Initiated	Piper Sandler	Overweight
Aug-12-20	Downgrade	BofA Securities	Neutral → Underperform
Aug-12-20	Reiterated	H.C. Wainwright	Buy
Aug-12-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-19-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-17-20	Initiated	BTIG Research	Buy
Oct-03-19	Initiated	H.C. Wainwright	Buy
Aug-12-19	Initiated	BofA/Merrill	Buy

View All

Fulcrum Therapeutics Inc Stock (FULC) Latest News

02:04 AM